Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an update.
Shanghai Fosun Pharmaceutical has completed the issuance of its first tranche of 2026 scientific and technological innovation bonds under a previously approved RMB4 billion medium-term note registration, continuing its strategy of tapping China’s interbank bond market to support innovation-related funding needs. The new issue totals RMB1 billion of two-year bonds with a 2.4% coupon, following earlier 2025 innovation bond tranches, and underscores the company’s ongoing access to relatively low-cost debt financing that may bolster liquidity and fund technology-driven projects, with several domestic banks acting as lead and joint lead underwriters.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based pharmaceutical and healthcare group engaged in the research, development, manufacturing and distribution of medicines and medical products, with a focus on innovation-driven growth and financing via domestic capital markets.
Average Trading Volume: 3,980,291
Technical Sentiment Signal: Hold
Current Market Cap: HK$74.73B
For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.